Sells over-the-counter consumer healthcare products in India, with four reporting segments. OTC Products is the core franchise, contributing 65.3% of FY26 segment revenue at Rs 328.32 crore, built around pain-relief brands including Back Pain Roll On and Head Roll On, which grew 12% and 21% respectively. Women's Hygiene & Personal Care accounts for 27.8% (Rs 139.91 crore), led by the Comfy XL variant which grew 44%. Beverages make up 6.3% (Rs 31.56 crore) and Others 0.6%. Only OTC Products is profitable at the segment level (EBIT Rs 83.44 crore), while Women's Hygiene, Beverages and Others each reported negative EBIT in FY26. Distribution was expanded during the year — stockist network up 9%, outlet coverage up 12%, and 44,000 new chemist outlets added, with a stated target of 100,000 chemist outlets by September 2027. New product launches included razors, antiseptic plaster, ortho pain oil and a nasal spray. The cost base is dominated by other operating expenses at 23.6% of revenue and materials at 21.2%, with employees at 12.7% and depreciation at 1.3%; capex was 10.9% of revenue. AR · MarketPing reader · 2026-08-02
Revenue streams, as the annual report describes them. OTC Products (65%), Women's Hygiene & Personal Care (28%), Beverages (6%), Others (1%). Brand-led, distribution-driven consumer healthcare business with concentrated dependence on OTC pain management
| ₹ crore · consolidated | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 406 | 380 | 421 | 452 | 503 |
| EBITDA (ex other income) | 79 | 44 | 51 | 58 | 67 |
| margin % | 19.6 | 11.7 | 12.2 | 12.9 | 13.3 |
| Owners' profit | 67 | 40 | 45 | 51 | 58 |
| EPS, as reported (₹) | 23.05 | 13.65 | 15.56 | 17.58 | 20.03 |
| ROE % · ROCE % | 25.3 · 33.4 | 13.7 · 18.0 | 15.6 · 20.9 | 15.6 · 20.6 | 15.6 · 20.4 |
| Debt / equity (x) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from operations | 53 | 19 | 28 | 51 | 36 |
| Capex | (23) | (9) | (7) | (36) | (55) |
| ₹ crore | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 110 | 123 | 135 | 94 | 118 | 141 | 150 | 103 |
| Profit before tax | 16 | 26 | 21 | 11 | 19 | 26 | 21 | 6 |
| Net profit | 12 | 19 | 15 | 8 | 14 | 19 | 16 | 4 |
| EPS (₹) | 4.08 | 6.66 | 5.25 | 2.87 | 4.83 | 6.73 | 5.60 | 1.51 |
| Segment | Revenue, ₹ crore | Share % |
|---|---|---|
| OTC Products | 328 | 65.3 |
| Women's Hygiene & Personal Care | 42 | 8.3 |
| Beverages | 32 | 6.3 |
| Others | 3 | 0.6 |
| Women's Hygiene | 98 | 19.5 |
| Total, before eliminations | 503 | 100.0 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| SUN PHARMACEUTICAL IND L | 4,41,471 |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 28 Aug 2026 · Amrutanjan Health files BRSR for FY 2025-26 | compliance | low | — | — |
| 28 Aug 2026 · Amrutanjan Health Care 89th AGM notice set for September 23, 2026 | board shareholder meetings | low | — | — |
| 12 Aug 2026 · Q1 FY27: Sales up 9%, PAT down on one-time charge; Comfy grows 27% | investor communications | medium | — | — |
| 11 Aug 2026 · Record date set at September 11 for FY26 final dividend | corporate actions | high | — | — |
| 11 Aug 2026 · Q1 FY27 results: Revenue up 9.5%, PAT falls 47%, exceptional items weigh | results | high | — | — |
| 6 Aug 2026 · Explanation for delay in Credit Rating disclosure filing | compliance | low | — | — |
| 5 Aug 2026 · Board meeting on Aug 11 to consider Q1 FY27 results | results | low | — | — |
| 5 Aug 2026 · Amrutanjan commissions 150 crore sanitary napkin plant in Telangana | capex operations | high | — | — |
| 5 Aug 2026 · CARE assigns A with Stable outlook to Amrutanjan Health Care issuer rating | credit debt | medium | — | — |
| 5 Aug 2026 · DSP Mutual Fund sells 2.11 lakh shares of Amrutanjan Health, holding drops to 2.82% | ownership changes | medium | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions |
| 36.5 |
| 5.26 |
| 23.7 |
| 13.7 |
| 17.5 |
| 11.8 |
| 32.3 |
| DIVI S LABORATORIES LTD | 2,47,033 | 84.6 | 14.74 | 63.7 | 15.3 | 18.8 | 8.7 | 42.8 |
| TORRENT PHARMACEUTICALS L | 1,68,062 | 79.3 | 9.56 | 41.5 | 12.2 | 8.0 | 11.8 | 33.1 |
| ZYDUS LIFESCIENCES LTD | 1,11,686 | 24.9 | 3.78 | 14.5 | 17.3 | 18.0 | 12.4 | 25.2 |
| CIPLA LTD | 1,10,352 | 32.7 | 3.20 | 16.9 | 11.2 | 14.7 | 8.0 | 19.7 |
| LAURUS LABS LIMITED | 1,06,375 | 97.2 | 19.59 | 59.3 | 16.4 | 17.2 | 7.2 | 32.0 |
| DR. REDDY S LABORATORIES | 97,319 | 30.1 | 2.55 | 13.1 | 10.9 | 13.0 | 12.1 | 15.0 |
| AUROBINDO PHARMA LTD | 96,656 | 26.3 | 2.55 | 13.4 | 9.2 | 12.6 | 6.3 | 23.0 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 26.3 | 28.9 | 76 of 169 | 55% |
| P/B | 3.8 | 3.3 | 95 of 163 | 42% |
| ROCE | 20.4 | 10.8 | 33 of 183 | 82% |
| ROE | 15.6 | 10.4 | 45 of 171 | 74% |
| Debt / Equity | 0.0 | 0.1 | 6 of 171 | 77% |
| EBITDA margin | 7.8 | 17.5 | 128 of 165 | 23% |
| Revenue growth | 9.5 | 16.3 | 96 of 161 | 41% |
| Profit growth | (47.5) | 30.9 | 132 of 158 | 17% |
| Market cap | 1419 | 839 | 83 of 182 | 55% |
| an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
